These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Pharmacokinetic study of different doses of Depo Provera. Fotherby K; Koetsawang S; Mathrubutham M Contraception; 1980 Nov; 22(5):527-36. PubMed ID: 6451351 [TBL] [Abstract][Full Text] [Related]
24. Depressive symptoms and Depo-Provera. Westhoff C; Truman C; Kalmuss D; Cushman L; Davidson A; Rulin M; Heartwell S Contraception; 1998 Apr; 57(4):237-40. PubMed ID: 9649914 [TBL] [Abstract][Full Text] [Related]
25. Prevalence of visible disruption of cervical epithelium and cervical ectopy in African women using Depo-Provera. Kuhn L; Denny L; Pollack AE; Wright TC Contraception; 1999 Jun; 59(6):363-7. PubMed ID: 10518230 [TBL] [Abstract][Full Text] [Related]
26. Exogenous progestins and breast cancer. Stanford JL; Thomas DB Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216 [TBL] [Abstract][Full Text] [Related]
27. Extracts from the report on the Joint IGCC/IFRP East and South East Asia Seminar on Regional Fertility Research. Mcdaniel EB IGCC News; 1980 Jan; 5(3):1-4. PubMed ID: 12179403 [TBL] [Abstract][Full Text] [Related]
28. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus. Petta CA; Faundes A; Dunson TR; Ramos M; DeLucio M; Faundes D; Bahamondes L Fertil Steril; 1998 Feb; 69(2):252-7. PubMed ID: 9496338 [TBL] [Abstract][Full Text] [Related]
29. Medroxyprogesterone acetate [Depo Provera] injections. Development of striae. Gupta M Br J Fam Plann; 2000 Apr; 26(2):104-5. PubMed ID: 10773604 [TBL] [Abstract][Full Text] [Related]
31. Injectable contraceptives: how safe are they? Initiatives Popul; 1979; 5(4):2-10. PubMed ID: 12338524 [TBL] [Abstract][Full Text] [Related]
32. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. de Abood M; de Castillo Z; Guerrero F; Espino M; Austin KL Contraception; 1997 Nov; 56(5):313-6. PubMed ID: 9437560 [TBL] [Abstract][Full Text] [Related]
34. Drug regulation in the United States and the United Kingdom: the Depo-Provera story. Richard BW; Lasagna L Ann Intern Med; 1987 Jun; 106(6):886-91. PubMed ID: 2953290 [TBL] [Abstract][Full Text] [Related]
35. Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent. Jeppsson S; Gershagen S; Johansson ED; Rannevik G Acta Endocrinol (Copenh); 1982 Mar; 99(3):339-43. PubMed ID: 6461995 [TBL] [Abstract][Full Text] [Related]
36. The use of Depo-Provera in East London. Savage W Fertil Contracept; 1978 Jul; 2(3):41-7. PubMed ID: 12260723 [TBL] [Abstract][Full Text] [Related]
37. Reply to Dr. Edwin B. McDaniel. Exaggerated claims of depo-provera safety. Minkin SF Women Health; 1981; 6(1-2):125-9. PubMed ID: 6223451 [TBL] [Abstract][Full Text] [Related]
38. DMPA use above the age of 35 in Thai women. Taneepanichskul S; Reinprayoon D; Phaosavadi S Contraception; 2000 Apr; 61(4):281-2. PubMed ID: 10899485 [TBL] [Abstract][Full Text] [Related]
39. FDA gives final approval to Depo amid concerns over safety, cost and coercion. Wash Memo Alan Guttmacher Inst; 1992 Nov; (17):2-3. PubMed ID: 12344620 [TBL] [Abstract][Full Text] [Related]